Q-omics provides the consensus-scored CCER2 profile across patient tissues and cancer cell-line models. CCER2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CCER2 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, CCER2 RNA expression shows 17,173 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KICH, and TGCT as cancer lineages where CCER2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCER2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCER2 survival associations across molecular data types. CCER2 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCER2 RNA expression–survival associations across cancer types. High CCER2 expression shows unfavorable associations in ACC, KIRC and LGG, but favorable associations in HNSC, SCLC and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CCER2 RNA expression.
This table summarizes CCER2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CCER2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCER2 shows lower tumor expression in KICH, HNSC and BRCA and higher tumor expression in KIRC, LIHC and COAD. The KICH box plot shows higher CCER2 RNA expression in normal versus tumor tissue (log2 FC = −0.655, t-test p < 0.001).
This table shows molecular features associated with CCER2 in patient tissues and cancer cell lines. In patient samples, CCER2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CCER2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE.
